HEP DART 2021: FRONTIERS IN DRUG DEVELOPMENT FOR HEPATOLOGY

HEP DART 2021：肝病药物开发前沿

• 批准号: 10391910
• 负责人: Raymond Felix Schinazi
• 金额: $ 1.2万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-11-04 至 2022-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10391910
• 关键词: Accreditation; Address; Adolescent; Advocate; Applications Grants; Area; Atmosphere; Award; Biology; COVID-19; COVID-19 pandemic; Categories; Chemistry; Clinical; Clinical Research; Combined Modality Therapy; Communities; Development; Disease; Disease Outcome; Doctor of Philosophy; Educational workshop; Ensure; Epidemiology; Event; Faculty; Fibrosis; Flare; Future; Grant; Guidelines; HIV; Health Personnel; Health Professional; Hepatitis; Hepatitis B Therapy; Hepatitis B Virus; Hepatitis C; Hepatitis C virus; Hepatology; Immunity; Immunotherapy; Infection; International; Knowledge; Learning; Liver diseases; Malignant Neoplasms; Medical; Minority; Nurses; Oral; Pediatrics; Persons; Pharmacology; Physician Assistants; Physicians; Population; Postdoctoral Fellow; Primary carcinoma of the liver cells; Process; Public Health; Regimen; Research Personnel; Role; Scholarship; Scientist; Stream; Therapeutic; Training; Travel; Treatment Protocols; Treatment outcome; United States National Institutes of Health; Universities; Vaccination; Vaccines; Viral Pathogenesis; Viral hepatitis; Virus; Virus Diseases; Woman; Work; chronic liver disease; clinical development; co-infection; continuing medical education; cost; drug development; frontier; graduate student; improved; interest; liver infection; meetings; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel marker; posters; prevent; programs; symposium; therapeutic development; therapeutic vaccine; therapy development; vaccine development; vaccinology; virtual

Abstract/ Project summary: HEP DART 2021: Frontiers in Drug Development for Hepatology HEP DART: Frontiers in Drug Development for Hepatology is an independent biennial conference attracting at least 250 attendees per meeting for the past 24 years. HEP DART is open to anyone interested in therapies for viral hepatitis and chronic liver disease. The content of this conference was developed to interest primarily scientists and clinical researchers with a focus on drug development and vaccinology. The aim of HEP DART 2021 is to assemble clinicians, researchers, basic scientists, nurses, physician assistants and advocates together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). HEP DART will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for liver infection, disease and cancer. OBJECTIVES: (1) Highlight advances in drug development against viral hepatitis such as HBV, HCV, and HDV. (2) Evaluate the progress toward the elimination of HBV and HCV as public health threats in the context of the COVID-19 pandemic. (3) Describe the latest developments in HBV curative strategies, including combination therapy for cure. (4) Highlight the latest findings in immunity, flares, immunotherapy and cure strategies. (5) Highlight advances in drug development against NASH, NAFLD, fibrosis and HCC. (6) Describe novel biomarkers for viral hepatitis, liver disease, and treatment outcomes. (7) Review the latest findings related to COVID-19 and liver disease. (8) Review current treatment and vaccination guidelines for viral hepatitis; describe advancements in improved treatment regimens. (9) Examine recent work and future directions for vaccines to prevent HCV infection. (10) Understand the consequences of HBV infection and NASH in pediatrics and adolescent populations. (11) Assess the role of therapeutic vaccines in future therapies for viral hepatitis, NASH, and co-infections with HIV. (12) Understand the epidemiology and pathogenesis of viral hepatitis including HBV-HDV, HCV, HAV and HEV. (13) Understand treatment in the context of co-infection with HIV and other viruses. METHODS: HEP DART 2021 comprises four days of in- person scientific presentations, delivered in both oral and poster presentations formats via non-concurrent sessions. Main sessions and keynote speakers will also be taped and streamed virtually shortly after the meeting. Emory University, Office of Continuing Medical Education will designate category 1 credits toward the AMA Physician’s Recognition Award to this accredited program. HEP DART provides a relaxed and scientifically stimulating atmosphere for both PhDs and MDs to network and learn together. Support is requested to help defray costs of scholarships and travel grants for young investigators, women, visible minorities and other under- represented delegates.

摘要/项目摘要：HEP DART 2021：肝脏病药物开发前沿 HEP DART：肝病药物开发前沿是一个独立的两年一度的会议，吸引了来自世界各地的专家， 在过去的24年里，每次会议至少有250名与会者。HEP DART向任何对以下疗法感兴趣的人开放： 病毒性肝炎和慢性肝病。这次会议的内容主要是为了引起人们的兴趣 科学家和临床研究人员，重点是药物开发和疫苗学。HEP DART的目的 2021年将聚集临床医生，研究人员，基础科学家，护士，医生助理和倡导者 共同推进我们对正在进行的病毒性肝炎治疗药物开发过程的了解 (HBV HCV、HDV、HAV和HEV）、非酒精性脂肪性肝炎（NASH）和肝细胞癌（HCC）。 HEP DART将独特地融合生物学、化学、药理学和临床研究领域， 科学界对当前和未来的治疗挑战有了更多的了解， 肝脏感染疾病和癌症。重点：（1）突出抗病毒药物开发的进展 肝炎如HBV、HCV和HDV。(2)评估消除HBV和HCV的进展， 在COVID-19大流行的背景下，公共卫生威胁。(3)描述HBV的最新发展 治疗策略，包括联合治疗。(4)重点介绍免疫学的最新发现耀斑 免疫疗法和治愈策略。(5)重点介绍针对NASH、NAFLD、纤维化的药物开发进展 和HCC。(6)描述病毒性肝炎、肝病和治疗结果的新型生物标志物。(7)审查 与COVID-19和肝病相关的最新发现。(8)审查目前的治疗和疫苗接种 病毒性肝炎指南;描述改进治疗方案的进展。(9)检查最近的工作 以及预防HCV感染的疫苗的未来方向。(10)了解HBV感染的后果 和NASH。(11)评估治疗性疫苗在未来的作用 治疗病毒性肝炎、NASH和HIV合并感染。(12)了解流行病学， 病毒性肝炎包括HBV-HDV、HCV、HAV和HEV的发病机制。(13)了解治疗 艾滋病毒和其他病毒的共同感染。方法：HEP DART 2021包括四天的 个人科学报告，以口头和海报报告的形式通过非并行方式进行 sessions.主要会议和主旨演讲者也将在会议结束后不久进行录制和虚拟直播。 埃默里大学，继续医学教育办公室将向AMA指定1类学分 医生的认可奖，以这个认可的计划。HEP DART提供了一个轻松而科学的 为博士和医学博士创造一种相互交流和共同学习的氛围。请求支持以帮助 为年轻调查员、妇女、明显的少数群体和其他不足的人支付奖学金和旅费补助金; 代表们。